ATE416157T1 - Inhibitoren von integrin alpha-v-beta-6 - Google Patents
Inhibitoren von integrin alpha-v-beta-6Info
- Publication number
- ATE416157T1 ATE416157T1 AT02724175T AT02724175T ATE416157T1 AT E416157 T1 ATE416157 T1 AT E416157T1 AT 02724175 T AT02724175 T AT 02724175T AT 02724175 T AT02724175 T AT 02724175T AT E416157 T1 ATE416157 T1 AT E416157T1
- Authority
- AT
- Austria
- Prior art keywords
- inhibitors
- beta
- integrin alpha
- novel
- integrin
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 108010044426 integrins Proteins 0.000 title abstract 2
- 102000006495 integrins Human genes 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 108010004788 integrin alphavbeta6 Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- AIDS & HIV (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10112771A DE10112771A1 (de) | 2001-03-16 | 2001-03-16 | Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE416157T1 true ATE416157T1 (de) | 2008-12-15 |
Family
ID=7677763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02724175T ATE416157T1 (de) | 2001-03-16 | 2002-02-21 | Inhibitoren von integrin alpha-v-beta-6 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7632951B2 (de) |
| EP (1) | EP1377540B1 (de) |
| JP (1) | JP4327461B2 (de) |
| CN (1) | CN1582271A (de) |
| AT (1) | ATE416157T1 (de) |
| AU (1) | AU2002254900B2 (de) |
| CA (1) | CA2440644C (de) |
| DE (2) | DE10112771A1 (de) |
| ES (1) | ES2316556T3 (de) |
| HU (1) | HUP0303514A2 (de) |
| MX (1) | MXPA03008215A (de) |
| WO (1) | WO2002074730A1 (de) |
| ZA (1) | ZA200308024B (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004255566B2 (en) * | 2003-07-07 | 2010-07-08 | Merk Patent Gmbh | Malonamide derivatives |
| CA2540730C (en) * | 2003-10-01 | 2012-08-21 | Merck Patent Gmbh | Alfavbeta3 and alfavbeta6 integrin antagonists as antifibrotic agents |
| WO2005034953A1 (ja) * | 2003-10-10 | 2005-04-21 | Kowa Co., Ltd. | 血管新生抑制薬 |
| US7939558B2 (en) | 2004-06-04 | 2011-05-10 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof |
| US7838252B2 (en) * | 2005-02-17 | 2010-11-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating a subject having an anthrax toxin mediated condition |
| WO2009048541A2 (en) * | 2007-10-05 | 2009-04-16 | Purdue Research Foundation | Compounds and methods for use in treating neoplasia and cancer |
| WO2009051910A1 (en) * | 2007-10-16 | 2009-04-23 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-cftr and uses thereof |
| ES2457822T3 (es) | 2007-11-08 | 2014-04-29 | The General Hospital Corporation | Procedimientos y composiciones de tratamiento de enfermedades proteinúricas |
| GB0922014D0 (en) * | 2009-12-17 | 2010-02-03 | Ge Healthcare Ltd | Novel integrin binders |
| WO2013016531A2 (en) * | 2011-07-26 | 2013-01-31 | Purdue Research Foundation | Compounds and methods for use in treating neoplasia and cancer |
| GB201305668D0 (en) * | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| WO2015179823A2 (en) * | 2014-05-23 | 2015-11-26 | The California Institute For Biomedical Research | Lung localized inhibitors of alpha(v)beta 6 |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| US20180110762A1 (en) * | 2015-03-26 | 2018-04-26 | Merck Sharp & Dohme Corp | Compositions Methods for Treating Chronic Kidney Disease |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| USRE50554E1 (en) | 2016-12-23 | 2025-08-26 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| MA52117A (fr) | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| US20180244648A1 (en) | 2017-02-28 | 2018-08-30 | Lazuli, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| SG11202002967SA (en) * | 2017-11-01 | 2020-05-28 | Arrowhead Pharmaceuticals Inc | Integrin ligands and uses thereof |
| TW202035400A (zh) | 2018-08-29 | 2020-10-01 | 美商莫菲克醫療股份有限公司 | 抑制αvβ6整合素 |
| HRP20250289T1 (hr) | 2018-08-29 | 2025-05-09 | Morphic Therapeutic, Inc. | Inhibitori za alfa v beta6 integrin |
| US20240209034A1 (en) * | 2021-04-12 | 2024-06-27 | University Of Washington | Engineering peptides for a a vb6 integrin binding and related methods of use and synthesis |
| WO2024218058A1 (en) * | 2023-04-17 | 2024-10-24 | Evotec International Gmbh | NOVEL COMPOUNDS AS α4β7 INHIBITORS |
| CN120309684A (zh) * | 2024-01-15 | 2025-07-15 | 武汉人福创新药物研发中心有限公司 | 靶向化合物及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6306840B1 (en) * | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| CA2371824A1 (en) | 1999-02-20 | 2000-08-24 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | .beta.-alanine derivatives |
| DE10041423A1 (de) | 2000-08-23 | 2002-03-07 | Merck Patent Gmbh | Biphenylderivate |
| DE10204789A1 (de) * | 2002-02-06 | 2003-08-14 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta6 |
-
2001
- 2001-03-16 DE DE10112771A patent/DE10112771A1/de not_active Withdrawn
-
2002
- 2002-02-21 CN CNA028067061A patent/CN1582271A/zh active Pending
- 2002-02-21 DE DE60230127T patent/DE60230127D1/de not_active Expired - Lifetime
- 2002-02-21 EP EP02724175A patent/EP1377540B1/de not_active Expired - Lifetime
- 2002-02-21 US US10/471,836 patent/US7632951B2/en not_active Expired - Fee Related
- 2002-02-21 WO PCT/EP2002/001836 patent/WO2002074730A1/en not_active Ceased
- 2002-02-21 HU HU0303514A patent/HUP0303514A2/hu unknown
- 2002-02-21 MX MXPA03008215A patent/MXPA03008215A/es unknown
- 2002-02-21 AU AU2002254900A patent/AU2002254900B2/en not_active Ceased
- 2002-02-21 JP JP2002573739A patent/JP4327461B2/ja not_active Expired - Fee Related
- 2002-02-21 AT AT02724175T patent/ATE416157T1/de not_active IP Right Cessation
- 2002-02-21 ES ES02724175T patent/ES2316556T3/es not_active Expired - Lifetime
- 2002-02-21 CA CA2440644A patent/CA2440644C/en not_active Expired - Fee Related
-
2003
- 2003-10-15 ZA ZA200308024A patent/ZA200308024B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP4327461B2 (ja) | 2009-09-09 |
| HUP0303514A2 (hu) | 2004-01-28 |
| ZA200308024B (en) | 2005-01-17 |
| JP2004525925A (ja) | 2004-08-26 |
| US20040092454A1 (en) | 2004-05-13 |
| ES2316556T3 (es) | 2009-04-16 |
| DE10112771A1 (de) | 2002-09-26 |
| DE60230127D1 (de) | 2009-01-15 |
| MXPA03008215A (es) | 2004-01-29 |
| CA2440644A1 (en) | 2002-09-26 |
| WO2002074730A1 (en) | 2002-09-26 |
| EP1377540A1 (de) | 2004-01-07 |
| CA2440644C (en) | 2011-10-18 |
| CN1582271A (zh) | 2005-02-16 |
| AU2002254900B2 (en) | 2008-04-10 |
| US7632951B2 (en) | 2009-12-15 |
| EP1377540B1 (de) | 2008-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60230127D1 (de) | Inhibitoren von integrin alpha-v-beta-6 | |
| SE0202463D0 (sv) | Novel compounds | |
| ATE394383T1 (de) | Biphenylkarbonsäureamidderivate als p38 kinase- inhibitoren | |
| DE60112974D1 (en) | Carbolinderivate | |
| NO20025821L (no) | 2-aminokarbonyl-9H-purinderivater | |
| DK1204654T3 (da) | Benzofurylpiperaziner og benzofurylhomopiperaziner: Serotonin agonister | |
| IS6658A (is) | Ný efnasambönd | |
| DE60121461D1 (de) | Kondensierte pyridoindolderivate | |
| ATE300543T1 (de) | Kondensierte pyrazindionderivate als pde5 inhibitore | |
| DE60216233D1 (en) | Carbolinderivate | |
| MXPA02012076A (es) | Compuestos quimicos. | |
| WO2003066594A3 (de) | 3-alkanoylamino-propionsäure-derivate als inhibitoren des integrins avss6 | |
| TR200201683T2 (tr) | İkameli fenil-piperazin türevleri, bunların hazırlanması ve kullanımları | |
| ATE318810T1 (de) | 3-oxadiazol-5-yl-1-aminoalkyl-1h-indolderivate | |
| DE60112960D1 (de) | Kondensierte pyridoindolderivate | |
| TR200201128T2 (tr) | PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri. | |
| ATE333457T1 (de) | Zyklische gmp-spezifische phosphodiesteraseinhibitoren | |
| DE60121048D1 (de) | PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE | |
| DE60110124D1 (de) | Kondensierte pyrazindionderivate als pde inhibitoren | |
| MXPA03003971A (es) | Derivados de indol como inhibidores de pde5. | |
| BR0110490B1 (pt) | agentes de tingimento contendo derivados de n-heteroarilmetil-m-fenilenodiamina para fibras de queratina bem como novos derivados de n-heteroarilmetil-m-fenilenodiamina. | |
| WO2002083627A3 (de) | Liganden des integrins alpha-v-beta-6 | |
| UY26329A1 (es) | Antagonistas de los receptores de vitronectina | |
| SE0102058D0 (sv) | New Salts II | |
| SE0403117D0 (sv) | New compounds 1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |